D
Dasan Pharmaceutical
Specialty drug delivery and formulation development services
About Dasan Pharmaceutical
Dasan Pharmaceutical, established as Dasan Medichem in July 1996 in South Korea, is a contract development and manufacturing organization (CDMO) that specializes in producing both active pharmaceutical ingredients (APIs) and finished pharmaceutical products. The company has a strong focus on research and development, particularly in Drug Delivery System (DDS) technologies, to enhance existing generic drugs. Its technical expertise includes micro-particle coating, fluidized bed coating, and oral delivery systems.
The company's business model encompasses providing CRO (Contract Research Organization) and CMO (Contract Manufacturing Organization) services, licensing its formulation technology, and consignment production for domestic and overseas pharmaceutical firms. Dasan offers a total service package that includes R&D, production, patent avoidance strategies, and assistance with government approvals for its clients. Its product portfolio is extensive, featuring microencapsulated drugs for taste-masking, controlled-release pellets, and treatments for chronic diseases like hypertension. Some of their products include microencapsulated Ibuprofen, Acetaminophen, and various antibiotics.
Significant milestones in the company's history include obtaining KGMP certification in 2008, establishing an R&D center in Shenyang, China in 2014, and changing its name from Dasan Medichem to Dasan Pharmaceutical in 2017. The company has received multiple awards for exports and being a youth-friendly employer. In September 2025, Dasan Pharmaceutical announced its plans to pursue a KOSDAQ listing to raise funds for expanding its manufacturing capabilities and targeting overseas markets. This was followed by a pre-IPO investment of $8.8 million in December 2025, led by KB Securities and NH Investment & Securities. The CEO is Hyung-seon Ryu.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Headquarters
- South Korea
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Chronic Disease, Biotech and Pharma
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Dec 2025 | $11M | $44M | NH Investment & Securities · KB Securities | ↗ |
Growth signals
Latest recorded traffic for Dasan Pharmaceutical is 3.7K monthly website visits, down 59.3% over the last three months. Dasan Pharmaceutical's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
NH Investment & Securities
KB Securities
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Dasan Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Dasan Pharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.